The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Clark PE, Spiess PE, Agarwal N, et al. NCCN guidelines insights: bladder cancer, version 2.2016. J Natl Compr Canc Netw. 2016;14(10):1213–1224. .
   PubMed Web of Science ®Google Scholar
• Pliarchopoulou K, Laschos K, Pectasides D. Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Urol Oncol. 2013;31(3):294–302.
   PubMed Web of Science ®Google Scholar
• Han S, Yang W, Zong S, et al. Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis. Oncotarget. 2017;8(38):64373–64384. .
   PubMedGoogle Scholar
• Ciurea ME, Georgescu AM, Purcaru SO, et al. Cancer stem cells: biological functions and therapeutically targeting. Int J Mol Sci. 2014;15(5):8169–8185. .
   PubMed Web of Science ®Google Scholar
• Malhi S, Gu X. Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach. Expert Opin Drug Deliv. 2015;12(7):1177–1201.
   PubMed Web of Science ®Google Scholar
• Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34(6):732–740.
   PubMed Web of Science ®Google Scholar
• Abe T, Fukuhara T, Wen X, et al. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with toll-like receptor 2 and hyaluronan. J Virol. 2012;86(11):6159–6170. .
   PubMed Web of Science ®Google Scholar
• Hu XT, Chen YW, Liang AC, et al. CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation. Blood. 2010;115(12):2458–2461. .
   PubMed Web of Science ®Google Scholar
• Nam K, Oh S, Lee KM, et al. CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells. Cell Signal. 2015;27(9):1882–1894.
   PubMed Web of Science ®Google Scholar
• Kung CI, Chen CY, Yang CC, et al. Enhanced membrane-type 1 matrix metalloproteinase expression by hyaluronan oligosaccharides in breast cancer cells facilitates CD44 cleavage and tumor cell migration. Oncol Rep. 2012;28(5):1808–1814.
   PubMed Web of Science ®Google Scholar
• Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–267.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Liao HX, Patton KL. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells. 1991;3(9):347–350.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4(9):1033–1043.
   PubMed Web of Science ®Google Scholar
• Morath I, Hartmann TN, Orian-Rousseau V. CD44: more than a mere stem cell marker. Int J Biochem Cell Biol. 2016;81(Pt A):166–173.
   PubMedGoogle Scholar
• Sacks JD, Barbolina MV. Expression and function of CD44 in epithelial ovarian carcinoma. Biomolecules. 2015;5(4):3051–3066.
   PubMed Web of Science ®Google Scholar
• Emich H, Chapireau D, Hutchison I, et al. The potential of CD44 as a diagnostic and prognostic tool in oral cancer. J Oral Pathol Med. 2015;44(6):393–400.
   PubMed Web of Science ®Google Scholar
• Heldin P, Basu K, Kozlova I, et al. HAS2 and CD44 in breast tumorigenesis. Adv Cancer Res. 2014;123:211–229.
   PubMed Web of Science ®Google Scholar
• Ghosh SC, Neslihan Alpay S, Klostergaard J. CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets. 2012;16(7):635–650.
   PubMed Web of Science ®Google Scholar
• Chen Y, Fu Z, Xu S, et al. The prognostic value of CD44 expression in gastric cancer: a meta-analysis. Biomed Pharmacother. 2014;68(6):693–697.
   PubMed Web of Science ®Google Scholar
• Baschnagel AM, Tonlaar N, Eskandari M, et al. Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas. J Oral Pathol Med. 2017;46(3):208–213.
   PubMed Web of Science ®Google Scholar
• Gvozdenovic A, Arlt MJ, Campanile C, et al. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res. 2013;28(4):838–847. .
   PubMed Web of Science ®Google Scholar
• Lipponen P, Aaltomaa S, Tammi R, et al. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer. 2001;37(7):849–856.
   PubMed Web of Science ®Google Scholar
• Kuncova J, Urban M, Mandys V. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. APMIS. 2007;115(11):1194–1205.
   PubMed Web of Science ®Google Scholar
• Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996;149(3):873–882.
   PubMed Web of Science ®Google Scholar
• Lipponen P, Aaltoma S, Kosma VM, et al. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol. 1998;186(2):157–164.
   PubMed Web of Science ®Google Scholar
• Gadalla HA, Kamel NA, Badary FA, et al. Expression of CD44 protein in bilharzial and non-bilharzial bladder cancers. BJU Int. 2004;93(1):151–155.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3673.
   PubMed Web of Science ®Google Scholar
• Han S, Huang T, Li W, et al. Association between hypoxia-inducible factor-2alpha (HIF-2alpha) expression and colorectal cancer and its prognostic role: a systematic analysis. Cell Physiol Biochem. 2018;48(2):516–527.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Wu CT, Lin WY, Chen WC, et al. Predictive value of CD44 in muscle-invasive bladder cancer and its relationship with IL-6 signaling. Ann Surg Oncol. 2018;25(12):3518–3526.
   PubMed Web of Science ®Google Scholar
• Wu CT, Lin WY, Chang YH, et al. Impact of CD44 expression on radiation response for bladder cancer. J Cancer. 2017;8(7):1137–1144.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Kakouratos C, Kalamida D, et al. Hypoxia-inducible proteins HIF1alpha and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. Int J Radiat Biol. 2016;92(7):353–363.
   PubMed Web of Science ®Google Scholar
• Afonso J, Santos LL, Miranda-Goncalves V, et al. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol Carcinog. 2015;54(11):1451–1466.
   PubMed Web of Science ®Google Scholar
• Hofner T, Macher-Goeppinger S, Klein C, et al. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urol Oncol. 2014;32(5):678–686. .
   PubMed Web of Science ®Google Scholar
• Oliva E, Pinheiro NF, Heney NM, et al. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Hum Pathol. 2013;44(5):860–866. .
   PubMed Web of Science ®Google Scholar
• Omran OM, Ata HS. CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer. Ultrastruct Pathol. 2012;36(3):145–152.
   PubMed Web of Science ®Google Scholar
• Kong QY, Liu J, Chen XY, et al. Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep. 2003;10(1):51–55.
   PubMed Web of Science ®Google Scholar
• Muller M, Heicappell R, Habermann F, et al. Expression of CD44V2 in transitional cell carcinoma of the urinary bladder and in urine. Urol Res. 1997;25(3):187–192.
   PubMedGoogle Scholar
• Woodman AC, Sugiyama M, Yoshida K, et al. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol. 1996;149(5):1519–1530.
   PubMed Web of Science ®Google Scholar
• Shen S, Xia JX, Wang J. Nanomedicine-mediated cancer stem cell therapy. Biomaterials. 2016;74:1–18.
   PubMed Web of Science ®Google Scholar
• Bomken S, Fiser K, Heidenreich O, et al. Understanding the cancer stem cell. Br J Cancer. 2010;103(4):439–445.
   PubMed Web of Science ®Google Scholar
• Wang L, Zuo X, Xie K, et al. The role of CD44 and cancer stem cells. Methods Mol Biol. 2018;1692:31–42.
   PubMedGoogle Scholar
• Cho SH, Park YS, Kim HJ, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 2012;41(1):211–218. .
   PubMed Web of Science ®Google Scholar
• Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 2015;8:3783–3792.
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–618.
   PubMed Web of Science ®Google Scholar